Analytical Data
-
Gene name
CYFIP1
- Application
-
Alternative Names
CY; CYFIP 1; CYFIP1; CYFP1_HUMAN; Cytoplasmic FMR1 interacting protein 1; Cytoplasmic FMR1-interacting protein 1; FLJ45151; KIAA0068; p140sra 1; p140sra-1; P140SRA1; Selective hybridizing clone; SHYC; Specifically Rac1 associated protein 1; Specifically Rac1-associated protein 1; SRA 1; Sra-1; SRA1
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q7L576
-
Expression Region
1-1253aa
-
AA Sequence
MAAQVTLEDALSNVDLLEELPLPDQQPCIEPPPSSLLYQPNFNTNFEDRNAFVTGIARYIEQATVHSSMNEMLEEGQEYAVMLYTWRSCSRAIPQVKCNEQPNRVEIYEKTVEVLEPEVTKLMNFMYFQRNAIERFCGEVRRLCHAERRKDFVSEAYLITLGKFINMFAVLDELKNMKCSVKNDHSAYKRAAQFLRKMADPQSIQESQNLSMFLANHNKITQSLQQQLEVISGYEELLADIVNLCVDYYENRMYLTPSEKHMLLKVMGFGLYLMDGSVSNIYKLDAKKRINLSKIDKYFKQLQVVPLFGDMQIELARYIKTSAHYEENKSRWTCTSSGSSPQYNICEQMIQIREDHMRFISELARYSNSEVVTGSGRQEAQKTDAEYRKLFDLALQGLQLLSQWSAHVMEVYSWKLVHPTDKYSNKDCPDSAEEYERATRYNYTSEEKFALVEVIAMIKGLQVLMGRMESVFNHAIRHTVYAALQDFSQVTLREPLRQAIKKKKNVIQSVLQAIRKTVCDWETGHEPFNDPALRGEKDPKSGFDIKVPRRAVGPSSTQLYMVRTMLESLIADKSGSKKTLRSSLEGPTILDIEKFHRESFFYTHLINFSETLQQCCDLSQLWFREFFLELTMGRRIQFPIEMSMPWILTDHILETKEASMMEYVLYSLDLYNDSAHYALTRFNKQFLYDEIEAEVNLCFDQFVYKLADQIFAYYKVMAGSLLLDKRLRSECKNQGATIHLPPSNRYETLLKQRHVQLLGRSIDLNRLITQRVSAAMYKSLELAIGRFESEDLTSIVELDGLLEINRMTHKLLSRYLTLDGFDAMFREANHNVSAPYGRITLHVFWELNYDFLPNYCYNGSTNRFVRTVLPFSQEFQRDKQPNAQPQYLHGSKALNLAYSSIYGSYRNFVGPPHFQVICRLLGYQGIAVVMEELLKVVKSLLQGTILQYVKTLMEVMPKICRLPRHEYGSPGILEFFHHQLKDIVEYAELKTVCFQNLREVGNAILFCLLIEQSLSLEEVCDLLHAAPFQNILPRVHVKEGERLDAKMKRLESKYAPLHLVPLIERLGTPQQIAIAREGDLLTKERLCCGLSMFEVILTRIRSFLDDPIWRGPLPSNGVMHVDECVEFHRLWSAMQFVYCIPVGTHEFTVEQCFGDGLHWAGCMIIVLLGQQRRFAVLDFCYHLLKVQKHDGKDEIIKNVPLKKMVERIRKFQILNDEIITILDKYLKSGDGEGTPVEHVRCFQPPIHQSLASS
-
Molecular Weight
145.1 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CYFIP1 (Cytoplasmic FMR1 Interacting Protein 1) is a crucial protein that plays a significant role in various cellular processes, including synaptic function, protein synthesis, and cellular signaling pathways. It interacts with the FMRP (Fragile X Mental Retardation Protein) and is implicated in the regulation of mRNA translation associated with synaptic plasticity, making it vital for learning and memory. Research into CYFIP1 has gained prominence due to its association with neurodevelopmental disorders, particularly Fragile X syndrome, which is the most common inherited form of intellectual disability. Variations and mutations in CYFIP1 have been linked to autism spectrum disorders and other neuropsychiatric conditions, highlighting the protein's importance in brain development and function. Given its critical role in neural and synaptic mechanisms, understanding the structural and functional properties of CYFIP1 can provide valuable insights into potential therapeutic strategies for these disorders. The recombinant expression and characterization of CYFIP1 is essential for elucidating its mechanisms of action, interactions with other proteins, and its impact on neuronal health, thereby contributing to the broader understanding of brain functionality and the pathogenesis of related diseases. Such research endeavors emphasize the need for advanced methodologies in protein expression and purification to analyze CYFIP1's behavior in physiological and pathological contexts, offering promising avenues for future studies in molecular neuroscience and therapeutic development.
